Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals (Nasdaq: CNTA), a clinical-stage pharmaceutical company, has announced its management team's participation in two upcoming investor conferences in June 2025:
- The Jefferies 2025 Global Healthcare Conference on June 4, with a fireside chat at 11:40 AM ET
- The Goldman Sachs 46th Annual Global Healthcare Conference on June 10, with a fireside chat at 9:20 AM ET
Live webcasts and archived recordings of both events will be accessible through the \"Events and Publications\" section on Centessa's investor relations website.
Centessa Pharmaceuticals (Nasdaq: CNTA), un'azienda farmaceutica in fase clinica, ha annunciato la partecipazione del suo team dirigenziale a due conferenze per investitori previste per giugno 2025:
- La Jefferies 2025 Global Healthcare Conference il 4 giugno, con un incontro informale alle 11:40 ET
- La Goldman Sachs 46th Annual Global Healthcare Conference il 10 giugno, con un incontro informale alle 9:20 ET
Le dirette web e le registrazioni archiviate di entrambi gli eventi saranno disponibili nella sezione "Eventi e Pubblicazioni" sul sito web delle relazioni con gli investitori di Centessa.
Centessa Pharmaceuticals (Nasdaq: CNTA), una empresa farmacéutica en etapa clínica, ha anunciado la participación de su equipo directivo en dos conferencias para inversores que se realizarán en junio de 2025:
- La Jefferies 2025 Global Healthcare Conference el 4 de junio, con una charla informal a las 11:40 AM ET
- La Goldman Sachs 46th Annual Global Healthcare Conference el 10 de junio, con una charla informal a las 9:20 AM ET
Las transmisiones en vivo y las grabaciones archivadas de ambos eventos estarán disponibles en la sección "Eventos y Publicaciones" en el sitio web de relaciones con inversores de Centessa.
Centessa Pharmaceuticals (나스�: CNTA), 임상 단계 제약 회사가 2025� 6월에 예정� � 개의 투자� 컨퍼런스� 경영진이 참여� 예정임을 발표했습니다:
- 6� 4� Jefferies 2025 Global Healthcare Conference, 오전 11:40 ET� 파이어사이드 채팅 진행
- 6� 10� Goldman Sachs 46th Annual Global Healthcare Conference, 오전 9:20 ET� 파이어사이드 채팅 진행
� 행사 모두� 생중� � 녹화본은 Centessa 투자� 관� 웹사이트� "이벤� � 출판�" 섹션에서 확인� � 있습니다.
Centessa Pharmaceuticals (Nasdaq : CNTA), une société pharmaceutique en phase clinique, a annoncé la participation de son équipe de direction à deux conférences pour investisseurs prévues en juin 2025 :
- La Jefferies 2025 Global Healthcare Conference le 4 juin, avec une discussion informelle à 11h40 ET
- La Goldman Sachs 46th Annual Global Healthcare Conference le 10 juin, avec une discussion informelle à 9h20 ET
Les webdiffusions en direct et les enregistrements archivés des deux événements seront accessibles dans la section « Événements et Publications » du site web des relations investisseurs de Centessa.
Centessa Pharmaceuticals (Nasdaq: CNTA), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat die Teilnahme seines Managementteams an zwei bevorstehenden Investorenkonferenzen im Juni 2025 angekündigt:
- Die Jefferies 2025 Global Healthcare Conference am 4. Juni mit einem Fireside Chat um 11:40 Uhr ET
- Die Goldman Sachs 46th Annual Global Healthcare Conference am 10. Juni mit einem Fireside Chat um 9:20 Uhr ET
Live-Webcasts und archivierte Aufzeichnungen beider Veranstaltungen sind im Bereich „Veranstaltungen und Publikationen� auf der Investor-Relations-Website von Centessa verfügbar.
- None.
- None.
BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Event: Jefferies 2025 Global Healthcare Conference
Date: June 4, 2025
Fireside Chat: 11:40 AM ET
Event: Goldman Sachs 46th Annual Global Healthcare Conference
Date: June 10, 2025
Fireside Chat: 9:20 AM ET
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications� tab on the investor relations section of the Centessa Pharmaceuticals website at .
About Centessa Pharmaceuticals
is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. We also have an early-stage immuno-oncology program focused on our novel LockBody® technology platform. For more information, visit , which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
